CDC logo, Safer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us




Uridine, 2' - deoxy - 5 - iodo -

RTECS #: YU7700000

CAS #: 54-42-2

UPDATE: August 2007 MW: 354.12 MF: C9H11IN2O5


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. REPRODUCTIVE EFFECTS DATA:
  4. TUMORIGENIC DATA:
  5. ACUTE TOXICITY DATA:
  6. OTHER MULTIPLE DOSE DATA:
  7. REVIEWS:
  8. NIOSH DOCUMENTATION AND SURVEILLANCE:
  9. STATUS IN FEDERAL AGENCIES:
  10. REFERENCES:

SYNONYMS:

  1. 1 - (2 - Deoxy - beta - D - ribofuranosyl) - 5 - iodouracil
  2. 1 - beta - D - 2' - Deoxyribofuranosyl - 5 - iodouracil
  3. 2' - Deoxy - 5 - iodouridine
  4. 5 - Iodo - 2' - deoxyuridine
  5. 5 - Iododeoxyuridine
  6. 5 - Iodouracil deoxyriboside
  7. 5IUDR
  8. Allergan 211
  9. Dendrid
  10. Emanil
  11. Herpesil
  12. Herpidu
  13. Herplex
  14. Herplex liquifilm
  15. IDU
  16. IDUR
  1. IUDR
  2. Idexur
  3. Idoxene
  4. Idoxuridin
  5. Idoxuridine
  6. Iducher
  7. Idulea
  8. Iduoculos
  9. Iduridin
  10. Joddeoxiuridin
  11. Kerecid
  12. NSC 39661
  13. Ophthalmadine
  14. SK&F 14287
  15. Stoxil
  16. Synmiol


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
cytogenetic analysis intraperitoneal
mouse 		133 mg/kg NULSAK 20,252,1977
DNA inhibition rabbit kidney 1 mg/L JMCMAR 24,390,1981
mutation in microorganisms other microorganisms 100 mg/L (-enzymatic activation step) MUREAV 267,125,1992
micronucleus test human lymphocyte 40 mg/L MUREAV 440,147,1999
mutation in mammalian somatic cells hamster lung 1 mg/L CRNGDP 6,1207,1985
mutation in mammalian somatic cells hamster ovary 16 mg/L TXAPA9 86,180,1986
mutation in mammalian somatic cells human HeLa cell 40 mg/L MUREAV 267,125,1992
mutation in mammalian somatic cells human fibroblast 15 mg/L CSHSAZ 29,151,1965
mutation in mammalian somatic cells human lymphocyte 100 µmol/L LIFSAK 19,563,1976
morphological transform hamster embryo 3,125 µg/L CNREA8 33,402,1973
phage inhibition capacity Escherichia coli 1 gm/L ZAPOAK 12,583,1972
sister chromatid exchange hamster ovary 128 mg/L TXAPA9 86,180,1986
sister chromatid exchange human lymphocyte 50 mg/L BMJOAE 283,817,1981
sister chromatid exchange human fibroblast 50 mg/L BMJOAE 283,817,1981
sister chromatid exchange parenteral
non-mammalian species 		1 mg/kg XISZD3 7,182,1985
specific locus test parenteral
Drosophila melanogaster 		14 mmol/L BCPCA6 15,299,1966
sperm morphology intraperitoneal
mouse 		100 mg/kg/5 day PNASA6 72,4425,1975


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 100 mg/kg (7 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) EXPEAM 29,198,1973
intraperitoneal
mouse 		lowest published toxic dose: 300 mg/kg (7 day pregnant) Reproductive: Specific developmental abnormalities: Central nervous system EXPEAM 29,198,1973
intraperitoneal
mouse 		lowest published toxic dose: 300 mg/kg (10 day pregnant) Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		EXPEAM 29,198,1973
ocular
rabbit 		lowest published toxic dose: 1,350 mg/kg (6-18 day pregnant) Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Specific developmental abnormalities: Eye, ear

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		AROPAW 93,46,1975
ocular
rabbit 		lowest published toxic dose: 3,250 µg/kg (6-18 day pregnant) Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Specific developmental abnormalities: Eye, ear

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		RIGAA3 26,631,1972
subcutaneous
mouse 		lowest published toxic dose: 600 mg/kg (16-18 day pregnant) Reproductive: Effects on newborn: Stillbirth TJADAB 11,103,1975
unreported route
mouse 		lowest published toxic dose: 300 mg/kg (10 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) 		TXAPA9 25,453,1973


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 100 mg/kg/8 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		EXPEAM 29,1132,1973


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lethal dose (50 percent kill): 1 gm/kg N/R JJIND8 62,911,1979
intraperitoneal
rat 		lethal dose (50 percent kill): 4 gm/kg N/R ADTEAS 3,181,1968
oral
mouse 		lethal dose (50 percent kill): >10 gm/kg N/R NIIRDN -,153,1995


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 4,589 mg/kg/18 day- intermittent Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field 		BCPCA6 3,110,1960


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
TOXICOLOGY REVIEW
SUOPH* 24,57,1979
TOXICOLOGY REVIEW
DIMON* 39,678,1993


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
N/R N/R N/R


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: X5053;
Number of Industries 1;
Total Number of Facilities 21;
Number of Occupations 2;
Total Number of Employees Exposed 618;
Total Number of Female Employees Exposed 318


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; Sperm morphology-mouse
EPA GENETOX PROGRAM 1988, Negative: SHE-clonal assay; Host-mediated assay
EPA GENETOX PROGRAM 1988, Negative: Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Negative: In vitro UDS-human fibroblast; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus; E coli polA without S9
EPA GENETOX PROGRAM 1988, Inconclusive: D melanogaster Sex-linked lethal
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Used as an antiviral agent
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001


REFERENCES:

CODEN
REFERENCE
ADTEAS Advances in Teratology. (New York, NY) V.1-5, 1966-72. Discontinued.
AROPAW Archives of Ophthalmology (Chicago). (AMA, 535 N. Dearborn St., Chicago, IL 60610) New series: V.1-44(3), 1929-50; V.64- 1960-
BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958-
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
CSHSAZ Cold Spring Harbor Symposia on Quantitative Biology. (Cold Spring Harbor Laboratory, POB 100, Cold Spring Harbor, NY 11724) V.1- 1933-
DIMON* Disease-a Month (Chicago : Year Book Publishers) V. 24- 1978-
EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963-
LIFSAK Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8, 1962-69; V.14- 1974-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan)
NULSAK Nucleus (Calcutta). (Dr. A.K. Sharma, Centre of Advanced Studies in Cell and Chromosome Research, Calcutta, 35 Baliygunge Circular Rd., Calcutta 700 019, India) V.1- 1958-
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915-
RIGAA3 Rinsho Ganka. Clinical Ophthalmology. (Igaku Shoin, 5-24-3 Hongo, Bunkyo-ku, Tokyo 113-91, Japan) V.1- 1947-
SUOPH* Survey of Ophthalmology (Elsevier Inc.) V.20- 1975-
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
XISZD3 Xibao Shengwuxue Zazhi. Journal of Cell Biology. (Shanghai Kexue Jishu Chubanshe, Shanghai, Peop. Rep. China) V.1- 1979-
ZAPOAK Zeitschrift fuer Allgemeine Mikrobiologie. (Akademie-Verlag GmbH, Postfach 1233, Berlin DDR-1086 Ger. Dem. Rep.) V.1- 1960-

Used as an antiviral agent

FDA-proprietary drug

RTECS Compound Description:
   Tumorigen
   Drug
   Mutagen
   Reproductive Effector
   Human Data

 Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  RTECS List |  Contact Us